Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development
Organic Process Research & Development2013Vol. 17(5), pp. 838–845
Citations Over TimeTop 10% of 2013 papers
Magnus Rönn, Zhijian Zhu, Philip C. Hogan, Wu‐Yan Zhang, John Yun Niu, C. E. Katz, Nicholas Dunwoody, Olga Gilicky, Yonghong Deng, Diana K. Hunt, Minsheng He, Chi-Li Chen, Cuixiang Sun, Roger B. Clark, Xiao-Yi Xiao
Abstract
Process research and development of the first fully synthetic broad spectrum 7-fluorotetracycline in clinical development is described. The process utilizes two key intermediates in a convergent approach. The key transformation is a Michael–Dieckmann reaction between a suitable substituted aromatic moiety and a key cyclohexenone derivative. Subsequent deprotection and acylation provide the desired active pharmaceutical ingredient in good overall yield.
Related Papers
- → Synthetic Approaches for the Construction of Five- and Six-Membered Silaazacycles(2022)15 cited
- → Synthesis and Shuttling Behavior of [2]Rotaxanes with a Pyrrole Moiety(2016)26 cited
- → Oxidation of Unsymmetrically Substituted Quaterthiophene with Two Terminal Ferrocenyl Groups(2009)11 cited
- Design, synthesis and evaluation of novel hydroxyethylamine derivatives with nitrogen heterocyclic moiety at N-terminal as BACE1 inhibitors(2010)
- STUDY ON INTRAMOLECULAR SYNERGISTIC INHIBITIVE EFFECTS OF BENZOTRIAZOLY MOIETY AND INIDAZOLY MOIETY(2009)